REGENXBIO — Third Quarter 2026 Earnings Summary

REGENXBIO reported a net loss of $40.7 million for the third quarter of 2026, driven by $61.0 million in research and development expenses, though this was partially offset by a $38.0 million gain from a litigation settlement with Sarepta Therapeutics. The company's cash position increased to $251.0 million as of September 30, 2026, following a $100.0 million milestone payment from AbbVie and proceeds from a public offering. Clinically, the company remains on track to submit a Biologics License Application for its Duchenne muscular dystrophy therapy, RGX-202, in the first quarter of 2027, while topline data from pivotal wet AMD studies is expected in the fourth quarter of 2026. Additionally, the company announced a clinical hold on its MPS II candidate, RGX-121, in August 2026 pending further evaluation of asymptomatic spine MRI findings.